Lurie Children's leads DIPG clinical trial

Diffuse intrinsic pontine glioma, known as DIPG, is a rare and aggressive type of pediatric cancer that forms in the brainstem, resulting in approximately 200 to 300 new cases in the United States each year. Fortunately, investigators at Lurie Children's are paving the way to breakthrough treatment for children with DIPG. In this podcast episode, Lurie Children’s physicians Dr. Ashley Plant-Fox and Dr. Michael DeCuypere discuss the progress of this first-of-its-kind clinical trial for DIPG that has been open since January of 2022 and offers hope for a disease that currently has no curative options. https://lnkd.in/gaqw4JVi

  • No alternative text description for this image

Ann & Robert H. Lurie Children's Hospital of Chicago It's inspiring to hear about the groundbreaking work being done to find treatment for DIPG. Thank you to Dr. Ashley Plant-Fox and Dr. Michael DeCuypere for their dedication to improving the lives of children affected by this rare and devastating cancer.

Amazing progress in the fight against DIPG! The hope this clinical trial brings to families is truly invaluable. Kudos to the team at Ann & Robert H. Lurie Children's Hospital of Chicago for their commitment to innovation and care.

Heather McNay

Marketing Specialist at Aleph Group, Inc.

1w

Incredible work being done by the team at Lurie Children's. Grateful for the ongoing efforts to change the future of pediatric cancer care. 🌿 #Hope

See more comments

To view or add a comment, sign in

Explore topics